Inventor · disambiguated record
Petinka Vlahova
Also filed as: VLAHOVA PETINKA · VLAHOVA PETINKA I · VLAHOVA PETINKA IVANOVA
27 granted patents·11 pending applications·223 citations·filing 2002–2024
96Inventor score
Files withBIOMED VALLEY DISCOVERIES INC6GUSHURST KAREN S5BRISTOL MYERS SQUIBB CO4VERTEX PHARMA3G1 THERAPEUTICS INC2
Top patents by PatentIndex Score
38 records- 0196US6605729B1Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)WARNER LAMBERT CO·Filed 2002·Granted Aug 12, 2003·104 cites·15 claims
- 0294US12139494B2Morphic forms of G1T38 and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2022·Granted Nov 12, 2024·3 cites·1 claims
- 0393US11261193B2Morphic forms of G1T38 and methods of manufacture thereofG1 THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·5 cites·20 claims
- 0493US9676746B2Crystalline forms of C21H22Cl2N4O2BIOMED VALLEY DISCOVERIES INC·Filed 2016·Granted Jun 13, 2017·6 cites·82 claims
- 0593US8067429B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2009·Granted Nov 29, 2011·23 cites·23 claims
- 0692US8569326B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2012·Granted Oct 29, 2013·16 cites·19 claims
- 0790US8486956B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2010·Granted Jul 16, 2013·13 cites·11 claims
- 0888US9273066B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS LTD·Filed 2013·Granted Mar 1, 2016·7 cites·20 claims
- 0987US12338249B2Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyureaSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2022·Granted Jun 24, 2025·1 cites·20 claims
- 1086US9034892B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS INC·Filed 2013·Granted May 19, 2015·6 cites·20 claims
- 1186US2025084059A1CRYSTALLINE FORMS OF C21H22Cl2N4O2BIOMED VALLEY DISCOVERIES INC·Filed 2024·Application pending·0 cites
- 1285US8754098B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2012·Granted Jun 17, 2014·5 cites·22 claims
- 1384US9120766B2Methods of making cocrystalsAPTUIT WEST LAFAYETTE LLC·Filed 2012·Granted Sep 1, 2015·7 cites·15 claims
- 1483US8513275B2Forms of rifaximin and uses thereofWU YIDUO·Filed 2011·Granted Aug 20, 2013·8 cites·6 claims
- 1582US10183927B2Crystalline forms of C21H22Cl2N4O2BIOMED VALLEY DISCOVERIES INC·Filed 2017·Granted Jan 22, 2019·2 cites·26 claims
- 1682US8815888B2Forms of rifaximin and uses thereofWU YIDUO·Filed 2013·Granted Aug 26, 2014·6 cites·20 claims
- 1780US12187698B2Crystalline forms of C21H22Cl2N4O2BIOMED VALLEY DISCOVERIES INC·Filed 2022·Granted Jan 7, 2025·0 cites·10 claims
- 1880US7144915B2Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)WARNER LAMBERT CO·Filed 2003·Granted Dec 5, 2006·9 cites·46 claims
- 1977US2025304592A1Morphic forms of g1t38 and methods of manufacture thereofPHARMACOSMOS HOLDING AS·Filed 2024·Application pending·0 cites
- 2073US10738027B2Crystalline forms of C21H22Cl2N4O2BIOMED VALLEY DISCOVERIES INC·Filed 2018·Granted Aug 11, 2020·0 cites·10 claims
- 2173US7829723B2Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-3-(3-methoxy-4-(oxazol-5-yl)phenyl)uriedo)phenyl)ethylcarbamateVERTEX PHARMA·Filed 2009·Granted Nov 9, 2010·1 cites·10 claims
- 2272US11390600B2Crystalline forms of C21H22Cl2N4O2BIOMED VALLEY DISCOVERIES INC·Filed 2020·Granted Jul 19, 2022·0 cites·10 claims
- 2372US7504515B2Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4- (oxazol-5-yl)phenyl) ureido)phenyl) ethylcarbamateVERTEX PHARMA·Filed 2006·Granted Mar 17, 2009·1 cites·10 claims
- 2471US2025026767A1Crystalline forms of a par4 inhibitorBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2569US12421195B2Amorphous and crystalline forms of IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Sep 23, 2025·0 cites·12 claims
- 2668US12129264B2Crystalline forms of a PAR4 inhibitorBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 29, 2024·0 cites·16 claims
- 2765US2008287521A1Crystalline Forms Of [R-(R*,R*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- Ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt (2:1)PFIZER·Filed 2008·Application pending·0 cites
- 2865US2025066382A1Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyureaSUMITOMO PHARMA SWITZERLAND GMBH·Filed 2024·Application pending·0 cites
- 2963US11236049B2Amorphous and crystalline forms of IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Feb 1, 2022·0 cites·4 claims
- 3063US2008214651A1Crystalline forms of [R-(R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)PFIZER·Filed 2007·Application pending·0 cites
- 3160US9546183B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS LTD·Filed 2016·Granted Jan 17, 2017·0 cites·4 claims
- 3257US2012076857A1Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2011·Application pending·0 cites
- 3356US2016097142A1Methods of making cocrystalsAMRI SSCI LLC·Filed 2015·Application pending·0 cites
- 3451US2022372044A1Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyureaMYOVANT SCIENCES GMBH·Filed 2022·Application pending·0 cites
- 3545US2011053997A1Salts and Crystal FormsBELIAEV ALEXANDER·Filed 2008·Application pending·0 cites
- 3640US9273038B2Solid forms of an ion channel modulatorGILEAD SCIENCES INC·Filed 2015·Granted Mar 1, 2016·0 cites·31 claims
- 3733US8536191B2Crystalline and amorphous forms of nalbuphine hydrochlorideHANKO JASON·Filed 2011·Granted Sep 17, 2013·0 cites·22 claims
- 3832US2011086891A1Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide)VERTEX PHARMA·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →